Merck & Co Inc

NYSE:MRK   10:10:11 AM EDT
+0.37 (+0.48%)

Merck Announces U.S. FDA Approval Of Vaxneuvance™ (Pneumococcal 15-Valent Conjugate Vaccine) For The Prevention Of Invasive Pneumococcal Disease In Adults 18 Years And Older Caused By 15 Serotyp

Published: 07/16/2021 21:22 GMT
Merck & Co Inc (MRK) - Merck Announces U.S. FDA Approval of Vaxneuvance™ (pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes.
Merck & Co Inc - Vaxneuvance Elicited Superior Immune Responses for Serotypes 3, 22f and 33f Compared to Pcv13, Which Are Major Causes of Disease.
Merck & Co - U.S. Cdc's Advisory Committee on Immunization Practices Expected to Meet in Oct to Make Recommendations on Use of Vaxneuvance in Adults.